Quick Answer
Nautilus Biotechnology, Inc. reported Total Assets of $191.11 million for fiscal year 2025.
Nautilus Biotechnology, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $191.11M | -21.3% |
| 2024 | $242.74M | -20.6% |
| 2023 | $305.56M | -12.7% |
| 2022 | $350.05M | -12.1% |
| 2021 | $398.45M | +368.7% |
| 2020 | $85.01M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $200.91M | -22.6% | -5.8% |
| June 30, 2025 | $213.19M | -21.8% | -6.4% |
| March 31, 2025 | $227.69M | -21.1% | -6.2% |
| December 31, 2024 | $242.74M | -20.6% | -6.5% |
| September 30, 2024 | $259.70M | -18.4% | -4.8% |
| June 30, 2024 | $272.75M | -17.5% | -5.5% |
| March 31, 2024 | $288.65M | -16.5% | -5.5% |
| December 31, 2023 | $305.56M | -12.7% | -4.0% |
- Nautilus Biotechnology, Inc. showed a decrease of -21.3% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Nautilus Biotechnology, Inc.’s total assets has grown by 124.8% (from $85.01 million to $191.11 million).
- The most recent figure is from Nautilus Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: